|
|
| (One intermediate revision by one other user not shown) |
| Line 1: |
Line 1: |
| '''FDA Pregnancy Category'''
| |
|
| |
|
| Initially developed in 1979 by US FDA to guide providers in interpretation of teratogenic risk associated with medications
| | #REDIRECT[[Drug pregnancy categories]] |
| | |
| | |
| *'''Category A''':
| |
| Adequate, well-controlled human studies have not shown increased risk to the fetus
| |
| | |
| | |
| *'''Category B''':
| |
| Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women
| |
| | |
| | |
| *'''Category C''':
| |
| Animal reproduction studies have shown an adverse effect on the fetus; there are no adequate and well-controlled studies in humans, and the benefits from the use of the drug in pregnant women may be acceptable despite its potential risks
| |
| | |
| | |
| *'''Category D''':
| |
| Well-controlled human studies have demonstrated fetal risk, but the benefit of use may be acceptable despite its potential risks
| |
| | |
| | |
| *'''Category X''':
| |
| Studies have demonstrated animal or human fetal abnormalities and the risk of the drug clearly outweighs the potential benefits
| |
| | |
| [[Category: Pharmacology]] | |
